tiprankstipranks
Salarius issued U.S. patent for next-gen targeted protein degraders
PremiumThe FlySalarius issued U.S. patent for next-gen targeted protein degraders
4M ago
Salarius announces Phase 1/2 trial of seclidemstat resumes patient enrollment
PremiumThe Fly
Salarius announces Phase 1/2 trial of seclidemstat resumes patient enrollment
4M ago
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
PremiumPress Releases
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
4M ago
Salarius Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
PremiumThe FlySalarius Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
9M ago
Salarius Pharmaceuticals explores strategic alternatives, begins cost savings
PremiumThe Fly
Salarius Pharmaceuticals explores strategic alternatives, begins cost savings
9M ago
Salarius Pharmaceuticals reports Q2 EPS ($1.43), consensus ($1.30)
PremiumThe Fly
Salarius Pharmaceuticals reports Q2 EPS ($1.43), consensus ($1.30)
9M ago
Salarius receives FDA clearance for IND application of SP-3164 Phase 1 trial
PremiumThe FlySalarius receives FDA clearance for IND application of SP-3164 Phase 1 trial
10M ago
Salarius presents SP-3164 targeted protein degrader preclinical data
PremiumThe Fly
Salarius presents SP-3164 targeted protein degrader preclinical data
11M ago
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
PremiumPress Releases
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100